HRP20201386T1 - Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat - Google Patents
Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat Download PDFInfo
- Publication number
- HRP20201386T1 HRP20201386T1 HRP20201386TT HRP20201386T HRP20201386T1 HR P20201386 T1 HRP20201386 T1 HR P20201386T1 HR P20201386T T HRP20201386T T HR P20201386TT HR P20201386 T HRP20201386 T HR P20201386T HR P20201386 T1 HRP20201386 T1 HR P20201386T1
- Authority
- HR
- Croatia
- Prior art keywords
- tablet
- pharmaceutical composition
- phosphate binder
- particles
- composition according
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims 18
- 239000002694 phosphate binding agent Substances 0.000 title claims 17
- 239000003826 tablet Substances 0.000 claims 17
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 claims 9
- 229960004158 sucroferric oxyhydroxide Drugs 0.000 claims 9
- 238000009826 distribution Methods 0.000 claims 6
- 238000012360 testing method Methods 0.000 claims 5
- 239000007891 compressed tablet Substances 0.000 claims 4
- 239000006186 oral dosage form Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 2
- 239000007900 aqueous suspension Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000007910 chewable tablet Substances 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (17)
1. Farmaceutska kompozicija za oralnu administraciju, koja sadrži vezivno sredstvo za fosfat, navedeno vezivno sredstvo za fosfat sadrži čestice koje imaju raspodjelu veličine čestica, gdje najmanje 40 % čestica ima veličinu čestica unutar opsega od 4 do 200 µm, d50 je u opsegu od između 40 µm do 100 µm, i gdje čestice vezivnog sredstva za fosfat sadrže smjesu željezo(III)-oksihidroksida, saharoze i jednog ili više škrobova, pri čemu je farmaceutska kompozicija komprimirana tableta ili tableta za žvakanje.
2. Farmaceutska kompozicija prema patentnom zahtjevu 1, koja sadrži smjesu škrobova.
3. Komprimirana tableta prema patentnom zahtjevu 1, koja sadrži sukroferi oksihidroksid kao čestice vezivnog sredstva za fosfat, i najmanje jedan dodatni farmaceutski prihvatljiv ekscipijens, i gdje najmanje 40%, ili najmanje 60%, ili najmanje 80%, ili najmanje 90% čestica u raspodijeli veličine čestica vezivnog sredstva za fosfat u tableti su između 4 do 200 µm, ili između 5 do 160 µm, ili između 21 do 160 µm.
4. Komprimirana tableta prema patentnom zahtjevu 1, koja sadrži sukroferi oksihidroksid kao čestice vezivnog sredstva za fosfat, i najmanje jedan dodatni farmaceutski prihvatljiv ekscipijens, i gdje čestice vezivnog sredstva za fosfat imaju raspodjelu veličine čestica sa d50 između 40 µm do 80 µm ili između 42 µm do 75 µm.
5. Komprimirana tableta prema bilo kojem od patentnih zahtjeva 1 do 4, gdje čestice vezivnog sredstva za fosfat imaju raspodjelu veličine čestica sa d50 između 40 µm do 80 µm i gdje najmanje 60%, ili najmanje 80% čestica raspodjele veličine čestica vezivnog sredstva za fosfat u tableti su između 4 do 200 µm ili između 5 do 160 µm ili između 21 do 160 µm.
6. Farmaceutska kompozicija prema patentnom zahtjevu 1, gdje jedna ili više ili sve od sljedećih karakteristika su postignute:
i) tvrdoća tablete je između 70 do 250 N, kako je mjereno u skladu sa Europskom farmakopejom 01/2008:20908 primjenom Schleuniger uređaja za ispitivanje čvrstoće pri drobljenju,
ii) lomljivost tablete je između 0% do 7% ili između 0.05% do 7%, kako je mjereno u skladu sa Europskom farmakopejom 01/2010:20907 Roche uređajem za ispitivanje lomljivosti,
iii) tableta ima vreme raspadanja manje od 30 min, ili između 5 do 20 min, kako je mjereno u skladu sa Europskom farmakopejom 04/2011:20901 standardnom opremom (Sotax DT3 uređaj za ispitivanje raspadljivosti),
iv) promjer tablete je između 16 mm do 30 mm, masa tablete je između 1500 mg do 3000 mg (poželjno 2000 do 3000 mg) i debljina tablete je između 4.5 mm i 7.5 mm.
7. Farmaceutska kompozicija prema patentnim zahtjevima 1 ili 6, gdje čestice vezivnog sredstva za fosfat sadrže sukroferi oksihidroksid, i gdje jedna ili više ili sve od sljedećih karakteristika su postignute:
i) najmanje 80% čestica u raspodijeli veličine čestica vezivnog sredstva za fosfat su između 4 do 200 µm,
ii) tvrdoća tablete je između 70 do 250 N, kako je mjereno u skladu sa Europskom farmakopejom 01/2008:20908 primjenom Schleuniger uređaja za ispitivanje čvrstoće pri drobljenju.
iii) lomljivost tablete je između 0% do 7%,, kako je mjereno u skladu sa Europskom farmakopejom 01/2010:20907 Roche uređajem za ispitivanje lomljivosti,
iv) tableta ima vreme raspadanja manje od 30 min, kako je mjereno u skladu sa Europskom farmakopejom 04/2011:20901 standardnom opremom (Sotax DT3 uređaj za ispitivanje raspadljivosti),
v) promjer tablete je između 16 mm do 30 mm i masa tablete je između 1500 mg do 3000 mg i debljina tablete je između 4.5 mm do 7.5 mm, i
vi) tableta sadrži između 1500 mg do 3000 mg sukroferi oksihidroksida.
8. Farmaceutska kompozicija prema bilo kojem od prethodnih patentnih zahtjeva 1, 6 i 7, koja je direktno komprimirana farmaceutska tableta.
9. Farmaceutska kompozicija prema bilo kojem od prethodnih patentnih zahtjeva 1, 6, 7 i 8, gdje čestice vezivnog sredstva za fosfat predstavljaju više od 65 % ukupne mase tablete (po masi na bazi suhe mase).
10. Farmaceutska kompozicija, prema bilo kojem od prethodnih patentnih zahtjeva, koja sadrži više od 80% sukroferi oksihidroksid čestica vezivnog sredstva za fosfat od ukupne mase farmaceutske kompozicije (po masi na bazi suhe mase).
11. Farmaceutska kompozicija, prema bilo kojem od prethodnih patentnih zahtjeva, koja sadrži više od 95% sukroferi oksihidroksid čestica vezivnog sredstva za fosfat od ukupne mase farmaceutske kompozicije (po masi na bazi suhe mase).
12. Farmaceutska kompozicija, prema bilo kojem od prethodnih patentnih zahtjeva, gdje pojedinačni oralni dozni oblik sadrži između 800 mg do 3500 mg sukroferi oksihidroksida.
13. Farmaceutska kompozicija, prema bilo kojem od prethodnih patentnih zahtjeva, gdje pojedinačni oralni dozni oblik sadrži između 2000 mg do 3000 mg sukroferi oksihidroksida.
14. Farmaceutska kompozicija, prema bilo kojem od prethodnih patentnih zahtjeva, gdje pojedinačni oralni dozni oblik sadrži 2500 mg sukroferi oksihidroksida.
15. Farmaceutska kompozicija prema bilo kojem od prethodnih patentnih zahtjeva, koja sadrži najmanje jedan dodatni farmaceutski prihvatljiv ekscipijens.
16. Farmaceutska kompozicija, prema bilo kojem od prethodnih patentnih zahtjeva za primjenu u sprečavanju i liječenju stanja hiperfosfatemije, naročito kod pacijenata sa kroničnom bubrežnom insuficijencijom.
17. Postupak za proizvodnju farmaceutske kompozicije kako je definirana u bilo kojem od prethodnih patentnih zahtjeva, koji obuhvaća korak sušenja raspršivanjem vodene suspenzije čestica vezivnog sredstva za fosfat, gdje vodena suspenzija čestica vezivnog sredstva za fosfat je podvrgnuta atomizaciji prije sušenja raspršivanjem.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13194632 | 2013-11-27 | ||
| EP14156793 | 2014-02-26 | ||
| EP14803118.0A EP3073997B1 (en) | 2013-11-27 | 2014-11-26 | Pharmaceutical composition, comprising phosphate binder particles |
| PCT/EP2014/075640 WO2015078900A1 (en) | 2013-11-27 | 2014-11-26 | Pharmaceutical composition, comprising phosphate binder particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201386T1 true HRP20201386T1 (hr) | 2020-12-25 |
Family
ID=51987152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201386TT HRP20201386T1 (hr) | 2013-11-27 | 2020-08-31 | Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US10624855B2 (hr) |
| EP (3) | EP3073997B1 (hr) |
| JP (4) | JP6431540B2 (hr) |
| CN (1) | CN105764492B (hr) |
| AU (3) | AU2014356500B2 (hr) |
| CA (1) | CA2931173C (hr) |
| CY (1) | CY1123956T1 (hr) |
| DK (1) | DK3073997T3 (hr) |
| ES (1) | ES2820737T3 (hr) |
| HR (1) | HRP20201386T1 (hr) |
| HU (1) | HUE051111T2 (hr) |
| LT (2) | LT3073997T (hr) |
| MX (1) | MX2016006916A (hr) |
| PL (1) | PL3073997T3 (hr) |
| PT (1) | PT3073997T (hr) |
| RS (1) | RS60894B1 (hr) |
| SI (1) | SI3073997T1 (hr) |
| WO (1) | WO2015078900A1 (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI468167B (zh) | 2007-11-16 | 2015-01-11 | 威佛（國際）股份有限公司 | 藥學組成物 |
| US20210308054A1 (en) | 2018-08-10 | 2021-10-07 | Kissei Pharmaceutical Co., Ltd. | Sucroferric oxyhydroxide-containing granules and pharmaceutical composition |
| CN109331036A (zh) * | 2018-10-17 | 2019-02-15 | 上海医药集团青岛国风药业股份有限公司 | 多糖铁在制备治疗高磷血症的药物中的应用 |
| CN109223824A (zh) * | 2018-11-23 | 2019-01-18 | 海南高升医药科技开发股份有限公司 | 一种治疗慢性肾病透析患者高磷血症的药物制备方法 |
| CN112972407A (zh) * | 2019-12-18 | 2021-06-18 | 南京恒生制药有限公司 | 一种碳酸司维拉姆片剂组合物及其制备方法 |
| KR20220154086A (ko) * | 2020-01-16 | 2022-11-21 | 비포 프레제니우스 메디컬 케어 레날 파마 리미티드 (비포 프레제니우스 메디컬 케어 레날 파마 아게) | 철(iii)-옥시하이드록사이드, 수크로스 및 하나 이상의 전분의 혼합물, 바람직하게는 수크로페릭 옥시하이드록사이드의 혼합물의 입자 |
| EP3932535A1 (en) | 2020-07-01 | 2022-01-05 | Vifor Fresenius Medical Care Renal Pharma, Ltd. | Manufacturing method for polynuclear iron compounds stabilized by carbohydrates and/or humic acid |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1249558A (en) | 1969-08-19 | 1971-10-13 | American Cyanamid Co | Process for the preparation of size-controlled colloidal iron sols and their stabilized solutions |
| DE4239442C2 (de) | 1992-11-24 | 2001-09-13 | Sebo Gmbh | Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten |
| DE19547356A1 (de) | 1995-12-19 | 1997-06-26 | Vifor Int Ag | Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung |
| US6117451A (en) | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
| WO2001089484A2 (en) * | 2000-05-22 | 2001-11-29 | Verion, Inc. | Method for increasing the compressibility of poorly binding powder materials |
| US6358526B1 (en) | 2000-08-16 | 2002-03-19 | Rexall Sundown | Method of making tablets and tablet compositions produced therefrom |
| DE102004031181A1 (de) * | 2004-06-28 | 2006-01-19 | Vifor (International) Ag | Phosphatadsorbens |
| MY157620A (en) * | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
| US20080014541A1 (en) | 2006-05-08 | 2008-01-17 | Bob Sonntag | Fluidizing nozzle for high capacity particulate loaders |
| KR100734922B1 (ko) | 2006-11-22 | 2007-07-03 | (주)스마트코퍼레이션 | 접합용 전자유도가열기 |
| PT2319804E (pt) * | 2006-12-14 | 2014-11-24 | Novartis Ag | Adsorvente de fosfato à base de ferro (iii)-carboidrato |
| EP1932807A1 (en) * | 2006-12-14 | 2008-06-18 | Novartis AG | Inorganic compounds |
| DE102007031984A1 (de) | 2007-07-10 | 2009-01-15 | Forschungszentrum Karlsruhe Gmbh | Reaktor zur hochspannungsimpulstechnischen Desinfektion bakterienverseuchter Flüssigkeiten und Verfahren dazu |
| GB0720220D0 (en) * | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
| TWI468167B (zh) | 2007-11-16 | 2015-01-11 | 威佛（國際）股份有限公司 | 藥學組成物 |
| GB0814326D0 (en) * | 2008-08-05 | 2008-09-10 | Medical Res Council | Phosphate binding materials and their uses |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
-
2014
- 2014-11-26 ES ES14803118T patent/ES2820737T3/es active Active
- 2014-11-26 RS RS20201051A patent/RS60894B1/sr unknown
- 2014-11-26 CN CN201480065206.0A patent/CN105764492B/zh active Active
- 2014-11-26 LT LTEP14803118.0T patent/LT3073997T/lt unknown
- 2014-11-26 MX MX2016006916A patent/MX2016006916A/es unknown
- 2014-11-26 JP JP2016534625A patent/JP6431540B2/ja active Active
- 2014-11-26 SI SI201431644T patent/SI3073997T1/sl unknown
- 2014-11-26 CA CA2931173A patent/CA2931173C/en active Active
- 2014-11-26 HU HUE14803118A patent/HUE051111T2/hu unknown
- 2014-11-26 AU AU2014356500A patent/AU2014356500B2/en active Active
- 2014-11-26 US US15/039,633 patent/US10624855B2/en active Active
- 2014-11-26 DK DK14803118.0T patent/DK3073997T3/da active
- 2014-11-26 EP EP14803118.0A patent/EP3073997B1/en active Active
- 2014-11-26 EP EP20177472.6A patent/EP3735962B1/en active Active
- 2014-11-26 LT LTEP20177472.6T patent/LT3735962T/lt unknown
- 2014-11-26 PT PT148031180T patent/PT3073997T/pt unknown
- 2014-11-26 PL PL14803118T patent/PL3073997T3/pl unknown
- 2014-11-26 WO PCT/EP2014/075640 patent/WO2015078900A1/en active Application Filing
- 2014-11-26 EP EP20177467.6A patent/EP3741360A1/en active Pending
-
2018
- 2018-05-16 JP JP2018094510A patent/JP6884124B2/ja active Active
-
2020
- 2020-03-16 US US16/820,190 patent/US11234938B2/en active Active
- 2020-03-16 US US16/820,177 patent/US11234937B2/en active Active
- 2020-08-12 AU AU2020217386A patent/AU2020217386B2/en active Active
- 2020-08-31 HR HRP20201386TT patent/HRP20201386T1/hr unknown
- 2020-09-03 CY CY20201100828T patent/CY1123956T1/el unknown
-
2021
- 2021-05-11 JP JP2021080281A patent/JP7335291B2/ja active Active
- 2021-12-16 US US17/644,612 patent/US11446252B2/en active Active
- 2021-12-16 US US17/644,599 patent/US11446251B2/en active Active
-
2022
- 2022-06-22 AU AU2022204380A patent/AU2022204380A1/en active Pending
- 2022-08-18 US US17/820,781 patent/US20220387327A1/en not_active Abandoned
-
2023
- 2023-08-17 JP JP2023132809A patent/JP2023175692A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201386T1 (hr) | Farmaceutska kompozicija, koja sadrži čestice vezivnog sredstva za fosfat | |
| Ngwuluka et al. | Formulation and evaluation of paracetamol tablets manufactured using the dried fruit of Phoenix dactylifera Linn as an excipient | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| AU2018253545A1 (en) | Microcrystalline diketopiperazine compositions and methods | |
| US11298330B2 (en) | Magnesium compositions and methods of use | |
| HRP20220929T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje astme | |
| AR085120A1 (es) | Formulaciones de particulas en polvo seco que contienen dos o mas ingredientes activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vias respiratorias | |
| WO2012107765A3 (en) | Particle formulation | |
| HRP20221432T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| NZ602000A (en) | Methods and compositions to treat hemorrhagic conditions of the brain | |
| HRP20211598T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20192227T1 (hr) | Dvojna uporaba oralnog farmaceutskog pripravka tableta sulfatnih soli i metode njihove uporabe | |
| NZ714517A (en) | Delayed release cysteamine bead formulation | |
| HRP20161624T1 (hr) | Produkt ko-mikronizacije koji sadrži ulipristal acetat | |
| HRP20200642T1 (hr) | Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin | |
| Okoye et al. | Formulation and Characterization of Moringa oleifera Leaf Granules. I: Micromeritic Properties. | |
| TW201129386A (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
| HRP20160774T1 (hr) | Pripravci za liječenje umora povezanog s karcinomom | |
| HRP20180103T1 (hr) | Farmaceutski oblici za oslobađanje aktivnih spojeva | |
| Sharada et al. | Sustained release matrix tablets of indomethacin using hibiscus rosa-sinensis as release retardant | |
| AU2014226192A8 (en) | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles | |
| HRP20150410T1 (hr) | Novi pripravci za terapiju esencijalne trombocitemije | |
| Agnihotri et al. | Formulation development and evaluation of antidiabetic polyherbal tablet | |
| JP2015120758A5 (hr) | ||
| HRP20221034T1 (hr) | Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća |